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Abstract
Routinelymeasurable biomarkers as predictors for adverse outcomes in febrile neutropenia could
improve management through risk stratification. This systematic review assesses the predictive
role of biomarkers in identifying events such as bacteraemia, clinically documented infections,
microbiologically documented infection, severe sepsis requiring intensive care or high depen-
dency care and death. This review collates 8319 episodes from 4843 patients. C-reactive pro-
tein (CRP), interleukin (IL)-6, IL-8 and procalcitonin (PCT) consistently predict bacteraemia and
severe sepsis; other outcomes have highly heterogeneous results. Performance of the biomarkers
at admission using different thresholds demonstrates that PCT > 0.5 ng/mL offers the best com-
promise between sensitivity and specificity: sensitivity 0.67 (confidence interval [CI] 0.53-0.79)
specificity 0.73 (CI 0.66-0.77). Seventeen studies describe the use of serial biomarkers, with PCT
having the greatest discriminatory role. Biomarkers, potentially with serial measurements, may
predict adverse outcomes in paediatric febrile neutropenia and their role in risk stratification is
promising.
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1 INTRODUCTION
Neutropenic sepsis, or febrile neutropenia (FN), remains a serious com-
plication of childhood cancer therapywith an incidence of bacteraemia
in 11-24% cases, paediatric intensive care unit (PICU) admissions in
0.9-11%cases, and fatality in 0.2-3% cases.1–8 For this reason, children
receiving anticancer treatment are frequently required to present to
hospital if they have a fever. Subsequently, they experience long hos-
pital admissions for treatment of FN despite data supporting safe and
effective use of risk-stratified early discharge.9–11
There are at least 25 different paediatric clinical decision rules
for the assessment of FN. These require local calibration before
Abbreviations: CDI, clinically documented infection; CI, confidence interval; CRP, C-reactive protein; FN, febrile neutropenia; FUO, fever of unknown origin; HSCT, hematopoietic stem cell
transplant; IL, interleukin; LOS, length of stay;MDI, microbiologically documented infection; PCT, procalcitonin; PICU, paediatric intensive care unit; QUADAS-2, Quality Assessment of
Diagnostic Accuracy Studies; ROC, receiver operating characteristic.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in anymedium, provided
the original work is properly cited.
c© 2019 The Authors. Pediatric Blood & Cancer Published byWiley Periodicals, Inc.
implementation, and lack of discriminatory value in the adolescents
and young adult (AYA) group suggests this groupmay need its own risk
predictionmodel.12–14
Biomarkers such as C-reactive protein (CRP) and procalcitonin
(PCT) have been used to fortify adult risk systems successfully.15,16
Three paediatric clinical decision rules have utilised biomarkers to
guide risk stratification (CRP in two rules and PCT in one17–19).
The International Pediatric Fever and Neutropenia Guideline Panel
and the National Institute of Clinical Excellence (NICE) have recom-
mended further research in the use of biomarkers for differentiat-
ing between low-, standard- or high-risk episodes and guide on-going
treatment.20,21
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Two previous systematic reviews have assessed the use of biomark-
ers in predicting adverse outcomes in febrile neutropenic episodes in
children and young people with cancer.22,23 These reviews showed
marked variation in terms of the quality of individual studies, biomark-
ers used and outcomesmeasured, whichmade it difficult tomake com-
parisons between thebiomarkers. Further studies havebeenpublished
since the last review in 2011, necessitating an updated systematic
review to evaluate the sensitivity and specificity of serum biomarkers
in predicting adverse outcomes in paediatric FN.
2 MATERIALS AND METHODS
This is an update of two preceding systematic reviews of the predictive
value of serumbiomarkers in the assessment andmanagement of fever
during neutropenia in children with cancer.22,23 The review protocol
was registered with the International register of systematic reviews
(PROSPERO) database of systematic reviews: CRD42016036350 in
March 2016 (https://www.crd.york.ac.uk/prospero/) .
2.1 Search strategy and selection criteria
The update search strategy mirrored the preceding reviews. It was
undertaken in April 2016 and further updated in November 2018
in MEDLINE, MEDLINE In-Process and Other Non-Indexed Cita-
tions, EMBASE, CINAHL, Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects, Health Technology
Assessment Database, Cochrane Central Register of Controlled Tri-
als, Web of Science Conference Proceedings Citation Index–Science
and Literatura Latinoamericana e do Caribe em Ciencias da Saude
(LILACS). The full electronic search strategy for the MEDLINE
database is provided in Supporting Information S1. Reference lists
of systematic reviews were examined for further relevant studies.
Published and unpublished studies were included. Language restric-
tions were not applied and relevant non-English language studies
were translated. Authors were contacted where further details were
required about study conduct or data.
The titles and abstracts of studies were screened by two indepen-
dent reviewers (TA and AH). Disagreements were resolved through
consensus or recourse to a third reviewer (RSP).
Studies deemed eligible for the systemic review included diag-
nostic cohort studies of patients receiving anticancer treatment for
solid, brain or haematological malignancies between the ages of 0 and
24 years, who presented to hospital or community settings with FN,
assessed a biomarker and its value in predicting an adverse outcome of
the FN episode.
The adverse outcomes considered included death, PICU/HDU (high
dependency unit) admission, single organ impairment, invasive bac-
terial or fungal infection, presence of microbiologically documented
infection (MDI) and presence of radiologically confirmed infection.
Studieswith combined adult and children populationswere excluded if
the outcome data for children or young people (0–24 years) could not
be reported separately.
2.2 Data extraction and risk of bias assessment
Datawere extracted by one reviewer using a standardised data extrac-
tion form, which had been used in the preceding systematic reviews,
and checked for accuracy independently by a second reviewer.
General data items extracted from the studies includeddemograph-
ics, geographical location, participant inclusion/exclusion criteria, clin-
ical characteristics and treatment course. Data were extracted for the
index tests (serum biomarker values) and adverse outcomes (e.g. sur-
vival, intensive/high dependency care admission, sepsis, bacteraemia).
Biomarker data for different cutoff values as well as different or serial
time points were obtained.
Studies were included if data could be extracted by either a 2 × 2
tables comparing dichotomized test results against the study adverse
outcome or by a measure of central tendency plus spread (e.g. mean
and standard deviation or median with range). If only the latter data
were available, it was converted using the assumption of normality and
2 × 2 tables derived for cut-offs reported in other studies.
Risk of bias was assessed using an adapted Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) tool, which had been used
in the preceding reviews. The quality item ‘time between index test
and reference test were appropriate’ was considered indiscriminate
because the index test (biomarker) and reference test (clinical out-
come) are always examined within a single episode of FN; the ‘inter-
mediate results’ outcome was deemed irrelevant as biomarker values
were required, so the ‘positive’, ‘intermediate’ and negative’ categories
were obsolete.
2.3 Methods of data synthesis
Quantitative pooling was performed for the commonest biomarkers if
therewas sufficient data formeta-analysis, where the same biomarker
for equivalent clinical outcomes was available. Where possible, the
groups were analysed for sources of heterogeneity. The MADA pack-
age was used in R to undertake the data pooling. The results are
displayed using cross-hairs plots in receiver operating characteristic
(ROC) space. This graphical approach combines the forest plot with
the ROC curve, showing study weight, the bivariate relationship of
sensitivity and specificity, and the confidence intervals around each
individual study as well as the overall pooled estimate.
3 RESULTS
The search strategy identified 509 articles ,of which 38 new articles
were included. Sixteen studies were excluded because data were not
extractable either by a 2 × 2 table of dichotomized data or by a mea-
sure of central tendency plus spread. Twenty-two remaining studies
with suitable quantitative data were combined with 21 studies from
the preceding two systematic reviews (Figure 1). Two further studies
were excludedbefore quantitative synthesis because therewere insuf-
ficient studies looking at similar outcomes using interleukin (IL)-1024
or insufficient numbers examining adrenomedullin.25
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F IGURE 1 Flowchart of study selection process
3.1 Study and population characteristics
Twenty-two new studies with quantitative data were identified in this
update comprising of 1851 patients and 3060 episodes. The new stud-
ies were geographically diverse (11 different countries) with an appro-
priate range of paediatric malignant diagnoses (Table 1). Themean age
of the patients within these studies was 6.7 years with an age range
between 0.3 and 23 years. One study did not provide data on patient
age.26 Hematopoietic stem cell transplant (HSCT) patients were not
represented in this population. The population characteristics of these
22 studies mirrored the population of the studies in the previous
reviews in terms of malignant diagnoses, age range, and lack of HSCT
patients.
Many biomarkers have been used to predict adverse outcomes in
paediatric FN but CRP, PCT, IL-6, and IL-8 remain the mostly com-
monly studied (13 studies, eight studies, eight studies and eight stud-
ies, respectively). Fourteen studies assessed more than one biomarker
in their populations, and seven studies assessed more than two
biomarkers. Biomarkers were tested at serial time points in 12 out of
22 studies.
The outcomes measures reported were infections (microbiologi-
cal or clinical), PICU, length of stay (LOS) in hospital, death and fever
of unknown origin (FUO). Infections were described as MDIs, clini-
cally documented infections (CDIs), bacteraemia, blood stream infec-
tion, severe infection, sepsis, severe sepsis and systemic infection. The
most commonly reported outcomes were bacteraemia, CDI, MDI and
FUO.
3.2 Risk of bias assessment
The summarised QUADAS-2 assessment of the 22 new studies is
shown in Figure 2; the quality assessment of individual studies is pro-
vided in Supporting Information S2.
The selection processwas inadequately described in 12 (55%) stud-
ies and three included studies were not cohort designed. Two of these
studies were case-control40,44 and one was a clinical trial.38 FN data
relating to biomarkers and outcomes were extractable from these
studies but case-control studies have been shown to exaggerate diag-
nostic accuracy estimates48 and the clinical trial data introduced bias
through non-blinding of the index test (biomarkers), using different
index tests in separate groups, and using the result of the index test to
define groups within the study.
FN was defined clearly within a study but varied between stud-
ies. This review found 17 definitions of FN including 16 for fever and
four for neutropenia. All studies, except one, included definitions of
fever to include a threshold of above 38◦C as a solitary (four studies)
or sustained (11 studies) temperature. One study differed by defining
fever as a solitary temperature over 38.5◦C. Twenty studies defined
neutropenia as a count below 0.5 × 109/L, although ‘falling counts’
under 1.0 × 109/L was accepted within six of these definitions. The
other two studies used falling counts under 0.75 × 109/L34 and under
1.0 × 109/L26 as definitions of neutropenia.
Descriptions of how multiple episodes were included in a study is
poorly described in most studies, as is whether the index test was
blindly interpreted without knowledge of the outcome. Descriptions
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TABLE 1 Population and study characteristics of 22 new studies in updated systematic review
Citation
Mean age, years
(range, years) Underlying conditions (n)
Markers studied [and time
point(s)]
Number of
patients
Number of
episodes Endpoints studied Comments on endpoints
Aggarwal
et al27
6 (2-13) ALL (40), NHL (6), AML (2) IL-5, IL-6, IL-8, TNF-�
[within 24 h]
48 52 CDI, MDI, FN related
death
Group 1=No focus of infection (low risk),
Group 2= clinical or radiological documented
focus of infection (high risk), Group
3=microbiologically proven infection or FN
related death (high risk)
Aquino
et al28
7.6 (± 3.3) ALL (36), AML (6), Solid (16) ESR, CRP, protein C level,
IFN-G, IL-1B, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10,
TNF-�, MIP-1a, MIP-1b,
MCP-1, exotoxin
[admission]
47 58 Bacteraemia
LOS
Badurdeen
et al26
Not stated ALL (22), AML (10), Lymphoma
(4), Bone sarcomas (5), soft
tissue sarcomas (6), CNS (6),
other malignancies (2)
IL-1, IL-5, IL-6, IL-8, IL-10,
IL-12p70, CRP [timing
unclear]
44 55 Bacteraemia
Chaudhary
et al29
6 (1-23) ALL/AML (20), RMS (2), HL (1),
ATRT (1), immature teratoma
(1), NBL (1)
IL-6, CRP
[days 1 and 3]
26 57 CDI, MDI, FUO MDI=≥1 blood culture positive, other positive
culture
Cost
et al30
Median 6.8 (no
range)
ALL (66), AML (9), CNS (13),
lymphoma (4), sarcomas (11),
other (13)
IL-1, IL-2, IL-4, IL-5, IL-6, IL-8,
IL-10, CRP, GMCSF, IFN-G,
TNF-� [<24 h]
116 195 Bacteraemia
PICU, death
PICU admission, fluid resus, and death
commented on but no data available with
biomarkers
Delebarre
et al31
7.6 (±5.1) ALL (54), AML (21), lymphoma
(19), bone (25), RMS (16), brain
(8), NBL (5), nephroblastoma
(5), others (6)
CRP, PCT [timing unclear] 160 372 Severe infection ‘Severe infection’ defined as bacteraemia,
positive culture of a normally sterile body
fluid, invasive fungal infection, localized
infection at risk of extension
Demirkaya
et al32
7.5 (1-18) Leukaemias (27), solid (7),
lymphoma (3)
Adrenomedullin, CRP, PCT
[days 0, 3, 7–10]
37 50 CDI, MDI, sepsis, severe
sepsis, Death, FUO
Sepsis-SIRS in presence of suspected/proven
infection. Severe sepsis-sepsis and cardiac or
ARDS, or twomore organ dysfunction
Hazan
et al33
9.5 (±5.9) Solid (75), nonsolid (120) CRP [admission, daily during
hospitalization]
73 195 Blood stream infection
(BSI)
Positive blood culture at admission, or≥10 days
after BSI episode, followed by disappearance
of first pathogen (three blood cultures),
CONS≥ 2 separate occasions
Hemming
et al34
Median 5.2
(1.3-18)
Solid (14), lymphomas (4),
leukaemias (9)
PCT [admission, days 2 and 3] 27 48 Severe infection
Non-severe infection
Severe and non-severe infection as per
PICNICC collaboration definition35
Kar et al36 Median 3.41
(5.75-11.9)
ALL (50), AML (8), NHL (7),
Hodgkin (1), NBL (1),Wilms (1)
CRP [admission] 68 200 CDI, MDI, fever of
unknown origin (FUO)
Kesik et al25 Median 10
(1.66-16)
PNET (2), Ewings (3), HL (2), NBL
(3), NHL (2), osteosarcoma (1),
ependymoma (1)
Adrenomedullin
[0 h, 24 h, 48 h, 7 days]
14 36 Culture positive
Culture negative
Culture positive—microorganism identified in
blood or urine
Mian et al37 Median 12
(2-21)
ALL (10), AML (5), NHL (1), bone
(6), RMS (3), CNS (4), NBL (4),
others (3)
Hs-CRP, PCT, IL-1�, IL-1� ,
IL-1Ra, IL-2, sIL-2Ra, IL-3,
4, 5, 6, 7, 8, 9, 10, IL-12,
TNF-�, and TNF-� [days 1
and 2]
36 89 High risk
Low risk
High risk: micropositive blood culture,
prolonged hospital stay (>7 days), admission
to PICU. Low risk; none of high-risk outcomes
(negative blood culture, pneumonia, colitis,
cellulitis)
(Continues)
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TABLE 1 (Continued)
Citation
Mean age, years
(range, years) Underlying conditions (n)
Markers studied [and time
point(s)]
Number of
patients
Number of
episodes Endpoints studied Comments on endpoints
Miedema
et al38
Median 1 (1-6) ALL (58), AML (13), lymphoma
(12), solid (42), brain (13),
other (3)
IL-8, CRP [admission and at
12-24 h]
141 233 Safety
Bacteraemia, LOS
Clinical trial primary outcome= safety (blood
culture positive, recurrent fever). Secondary
outcome= bacteraemia, duration of fever,
LOS, or complications (PICU
admission/death). IL-8 used to group low-risk
andmedium-risk episodes
Oberoi et al39 Median 5 (4-7) ALL only CRP [admission] 176 320 Complications (yes or
no)
Definition of complication; septic shock,
pneumonia (requiring invasive/non-invasive
support), renal failure, neutropenic
enterocolitis, encephalopathy, congestive
cardiac failure, mucosal bleeds, other
complications that were considered serious
and clinically significant
Penagos-
Paniagua
et al40
9.3 (± 3.9) ALL (49), AML (11), NHL (10),
soft tissue sarcomas (11), HL
(2), NBL (1), retinoblastoma
(1), other (6)
CRP [admission] 127 98 CDI, MDI, FUO
Reitman
et al41
8.6 Not stated PCT [admission and 12-24 h] 70 89 Bacteraemia Not defined
Santolaya
et al42
9.2 (no range) Leukemia (303), lymphoma (27),
solid (117) [episode data]
CRP, IL-8 [admission and
24 h]
403 447 Severe sepsis ‘Severe sepsis’ as per international definition43
Schroder and
Lodahl44
5.7 (0.3-15) Haematological cancer (45), solid
(40)
PCT, CRP [admission and
serial samples within 48 h,
timings unclear)
85 230 Systemic infection (SI)
Non-systemic
infection (NSI)
SI—culture positive bacteraemia. NSI—all other
causes of fever
Urbonas
et al45
7 (1-18) Haematological and
non-haematological cancers
(numbers unclear)
IL-6, IL-8 [days 1 and 2] 37 61 Bacteraemia/sepsis
group, FUO group
Bacteraemia/sepsis: positive blood culture,
clinically documented sepsis. FUO-negative
blood culture, absence of
clinical/microbiological signs of infection
Urbonas
et al24
3 (1-17) ALL (16), AML (2), NHL (1),
non-haematological cancer (5)
IL-10 [day 1] 24 36 Septic group, FUO group Septic: positive blood culture, clinically
documented sepsis
Urbonas
et al46
Median 6 (range
1–17)
ALL (28), AML (2), NHL (1),
non-haematological cancer (6)
PCT, IL-2R, sHLA-G, prespsin
[day 1]
37 62 Bacteraemia/sepsis
group, FUO group
Bacteraemia/sepsis: positive blood culture,
clinically documented sepsis
van der Galien
et al47
Median 6.3
(0.8-18.8)
Hematologic (44), solid (26),
brain (7)
IL-6, PCT [admission,
12-24 h]
55 77 Bacterial infection
No bacterial infection
Bacterial infection; blood culture, or culture of
fluid from otherwise sterile site, or
radiologically documented infection
Abbreviations: ALL, acute lymphoblastic leukemia; NHL, non-Hodgkins lymphoma; AML, acutemyeloid leukemia; CNS, central nervous system tumors; RMS, rhabdomyosarcomas; HL, Hodgkins lymphoma; ATRT,
atypical teratoid rhabdoid tumors; NB, neuroblastoma; PNET, primitive neuroectodermal tumors; IL, interleukin; ESR, erythrocyte sedimentation rate; IFN-� , interferon-gamma; MIP, macrophage inflammatory
protein;MCP, monocyte chemoattractant protein; GMCSF, granulocytemacrophage colony stimulating factor; sHLA-G, soluble human leukocyte antigen G.
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F IGURE 2 Overall summary of the quality of 22 new studies included in this updated review
of outcomes (reference standards) were explained well within studies
but descriptions of the same outcome, such as bacteraemia, sepsis and
severe infection, differedbetween studies.Definitions ofMDI,CDI and
FUO were similar between studies. Although measures of LOS, PICU
admission and death were reported, data were usually not presented
in context of biomarker levels against these outcomemeasures.
The timings of tests were not given in two studies.19,26 ‘Admission’
samples were reported as taken before the commencement of treat-
ment.Whenserial biomarkerswereused, timings variedbetweenstud-
ies andmissing values were unclear if mean results were given.
3.3 Quantitative synthesis
This updated review now collates 8315 FN episodes from 4822
patients evaluating 30 different biomarkers. The most common
biomarkers reported are CRP (42 studies), PCT (22 studies), IL-6
(20 studies) and IL-8 (13 studies). The next most frequently studied
biomarkers are tumour necrosis factor-alpha/-RII (TNF-� /-RII) with
nine studies, IL-5witheight studies, and IL-10and IL-2with seven stud-
ies each. The aggregate number of studies looking at other biomarkers
is shown in Supporting Information S3.Quantitative synthesiswas per-
formed on the four most common biomarkers due to the availability of
sufficient data on biomarker and similar outcomes.
Quantitative synthesis was possible for CRP and clinical bacterial
infections, bacteraemia, serious bacterial infections and severe sep-
sis; PCT and clinical bacterial infections, bacteraemia, microbiologi-
cally defined infections and serious bacterial infections; IL-6 and clin-
ical bacterial infections, bacteraemia, and serious bacterial infections;
and finally, IL-8 and clinical bacterial infections, bacteraemia, serious
bacterial infections and severe sepsis. There were insufficient data to
provide quantitative synthesis of outcomes such as LOS, PICU admis-
sions and death. The analyses per-outcome can be seen in Supporting
Information S4. The pooled sensitivity (pSn) and specificity (pSp) for
the biomarkers to detect any adverse outcome is CRP pSn 40% (95%
confidence interval [CI] 20-75%), pSp 65% (95%CI 30-85%); PCT pSn
60% (95% CI 35-80%), pSp 75% (95%CI 50-90%); IL-6 pSn 65% (95%
CI 20-85%), pSp 70% (95%CI 30-90%); and IL-8 pSn 70% (95% CI 40-
90%), pSp 60% (95%CI 25-80%).
Bivariate meta-analysis of the biomarkers at different cutoff lev-
els reiterates the expected relationship found in the previous reviews;
low biomarker cutoff levels predict adverse outcomes with great sen-
sitivity but poor specificity, and high biomarker cutoff levels predict
adverse outcomes with poor sensitivity but good specificity (Table 2).
The cross-hairs ROC plots (Figure 3A–D) displaying the predictive
ability of thebiomarkers at commonly reported cutoff points illustrates
imprecision within each study as well as between study heterogeneity.
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TABLE 2 Bivariate meta-analysis of CRP, PCT, IL-6, and IL-8 at different cutoff levels to detect any adverse outcome
Marker and cutoff
threshold
Number of
studies
Number of FN
episodes
Sensitivity (95%
confidence interval)
Specificity (95%
confidence interval)
CRP> 20mg/L 4 321 0.82 (0.58-0.94) 0.24 (0.15-0.35)
CRP> 50mg/L 9 1148 0.58 (0.37-0.77) 0.71 (0.64-0.78)
CRP> 90mg/L 9 1801 0.56 (0.40-0.70) 0.75 (0.58-0.87)
PCT> 0.2 ng/mL 8 661 0.80 (0.56-0.93) 0.60 (0.33-0.82)
PCT> 0.5 ng/mL 10 1204 0.67 (0.53-0.79) 0.73 (0.66-0.77)
PCT> 1.0 ng/mL 5 880 0.35 (0.21-0.52) 0.88 (0.65-0.87)
IL-6> 100 pg/mL 7 379 0.63 (0.52-0.72) 0.56 (0.34-0.75)
IL-6> 235 pg/mL 5 570 0.66 (0.29-0.90) 0.88 (0.73-0.95)
IL-6> 1000 pg/mL 4 502 0.15 (0.05-0.41) 0.97 (0.86-0.99)
IL-8> 100 pg/mL 8 660 0.80 (0.71-0.86) 0.48 (0.31-0.66)
IL-8> 320 pg/mL 6 952 0.47 (0.22-0.73) 0.81 (0.55-0.94)
IL-8> 500 pg/mL 3 455 0.22 (0.02-0.83) 0.90 (0.45-0.99)
IL-8> 1000 pg/mL 1 193 0.22 (0.02-0.83) 0.90 (0.45-0.99)
3.4 Comparison of biomarkers
Thirteen studies in this reviewusedmore than one biomarker and gave
comparative descriptions of performance.26–32,37,38,42,44,45,47 Three
out of the four studies comparing the performance of CRP and
PCT31,32,37,44 found the latter to be better at predicting adverse out-
comes. Such comparisons can be affected by the choice of cutoff, but
the following are consistent across thresholds. PCT appeared to be
more discriminatory at admission, whereas CRP was more discrimina-
tory after 48h. In oneof these comparative studies, CRPwasmore sen-
sitive but not more specific than PCT. CRP was also found to be more
sensitive but less specific in a study where its performance was com-
pared with IL8.42 There were seven studies evaluating CRP and IL-8
or IL-626,28–30,37,38,42 but only two compared their predictive capaci-
ties, finding that the ILs added greater predictive value than CRP.29,30
Five studies explored the predictive role of IL-6 and IL-8: one found
IL8 to perform better,30 one found them to be equivalent,45 and the
other threedid notmake any comparisons.26,27,37 Therewerenodirect
comparisons of PCT with IL-8 but one study compared the predictive
value of PCT to IL-6,47 finding that IL-6 demonstrated better discrimi-
natory power at admission and at 12-24 h of admission but particularly
at admission. The authors also found combining PCT (>0.25 ng/L) with
IL-6 (>60 ng/L), which significantly increased the likelihood of identify-
ing a bacterial infection at both time points.
3.5 Use of serial biomarkers
Eleven new studies in this systematic review assessed the four com-
monest biomarkers atmore thanone timepoint. Serial CRP levelswere
evaluated in seven studies, PCT in six studies, IL-8 in four studies and
IL-6 in four studies (Table 3). The description of the timings was often
unclear or varied; for example, studies describe the timing of the initial
biomarker as ‘admission’, ‘day0′ or ‘day1′.Meta-analysiswas not possi-
ble due to varying time points and outcomemeasures, and insufficient
data.
Four of seven studies evaluating serial CRPs described a better pre-
dictive value after 48 h than at admission, echoing five out of six stud-
ies showing serial PCTs were likely to be more useful than single PCTs.
The claimed benefit of serial IL-8 levels was inconsistent, and two of
the four IL-6 studies showed no benefit in serial assessment.
4 DISCUSSION
This systematic review includes 8315 FN episodes from 4822 patients
from 11 different countries. The age of patients represented in this
systematic reviewcharacterise thegeneral paediatric oncologypatient
population well. However, HSCT population is poorly represented in
these studies. This group is subject to more intense systemic anti-
cancer treatment, so there should be caution in extrapolating the
results of this review to HSCT patients.
The number of biomarkers being explored has doubled from 14 in
the original 2011 review to 30 in the 2018 update. Laboratory tech-
niques allow panels of multiple biomarkers to be explored simultane-
ously but small study numbers prevent meaningful quantitative syn-
thesis of such biomarkers. Interestingly, lactate was not explored as a
biomarker in any of these studies despite its incorporation in national
and international sepsis guidelines.49
The overall quality of studies included in this systematic review
was good with the greatest difficulties found in reporting whether the
biomarkerswere interpretedwithout knowledge of the outcome. Vari-
ation in the definition of FN has decreased in the updated 22 stud-
ies, this update with more consistency for fever to be defined as a
temperature over 38◦C and neutropenia as below 0.5 × 109/L. The
majority of studies did not clarify how multiple FN episodes in the
same patient would be defined. This could have affected the qual-
ity of their study if the episodes occurred within a short period of
time (i.e. biomarker had not returned to baseline levels) or there
was overrepresentation of patients with genetic predisposition to
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F IGURE 3 Cross-hairs ROC plot showing relationship of sensitivity and specificity at different cutoff levels of (A) PCT, (B) CRP, (C) IL-6, and (D)
IL-8. Crosses= individual studies; centre of cross= predictive value, length of cross=CIs within the study. Small circle= pooled predictive value
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TABLE 3 Serial biomarker studies in updated review describing time points for biomarker analysis, outcomes assessed, and study findings
Biomarker Study Time points (days) Outcomes assessed Reported findings
CRP Chaudhary et al29 1, 3 MDI, CDI Statistically significantly higher on 3 versus 1
forMDI (not CDI)
CRP Demirkaya et al32 0, 3, 7-10 MDI, CDI, sepsis, death Statistically significantly higher on 3 versus 0.
No difference 7-10.
CRP Hazan et al33 A, daily Bacteraemia Statistically significantly higher on A and 5-8 for
bacteraemia
CRP Mian et al37 1, 2 Bacteraemia, LOS, ICU No statistical difference
CRP Miedema et al38 A, 0.5-1 Bacteraemia, LOS, PICU, death Clinical trial, levels predetermined
CRP Santolaya et al42 A, 1 Severe sepsis Increase>100mg/L at 24 h risks severe sepsis
CRP Schroder and Lodahl44 A, unclear (within 2) Bacteraemia Description; discriminatory power better after
2 than A
PCT Demirkaya et al32 0, 3, 7-10 MDI, CDI, sepsis, death Statistically significantly lower on 3 versus
7-10. 0 versus 3 showed no difference
PCT Hemming et al34 0, 2, 3 SBI Description; rose on 2 versus 0 in three out of
three cases of SBI
PCT Mian et al37 1, 2 Bacteraemia, LOS, PICU No statistical difference
PCT Reitman et al41 A, 0.5-1 Bacteraemia Serial PCT is better than single PCT
PCT Schroder and Lodahl44 A, unclear (within 2) Bacteraemia Description; discriminatory power rises over
time
PCT Van der Galien et al47 A, 0.5-1 Bacterial infection Significantly higher at both time points and
discriminatory power increases with time
IL-8 Mian et al37 1, 2 Bacteraemia, LOS, PICU Statistically significantly lower on 2 versus 1
IL-8 Miedema et al38 A, 0.5-1 Bacteraemia, LOS, PICU, death Clinical trial, levels predetermined
IL-8 Santolaya et al42 A, 1 Severe sepsis Increase>300 pg/mL at 24 h risks severe sepsis
IL-8 Urbonas et al45 1, 2 Bacteraemia No benefit in doing serial IL-8
IL-6 Chaudhary et al29 1, 3 MDI, CDI Not statistically significantly different between
days 1 and 3
IL-6 Mian et al37 1, 2 Bacteraemia, LOS, ICU Statistically significantly lower on 2 versus 1
IL-6 Urbonas et al24 1, 2 Bacteraemia No benefit in doing serial IL-8
IL-6 Van der Galien et al47 A, 0.5-1 Bacterial infection Significantly higher at both time points and
discriminatory power decreases with time
Abbreviation: A, admission time-point.
infections, in their biomarker response, or fever without adverse
outcome.50
Episodes were not described in context of clinical features (e.g.
haemodynamic parameters, maximum/duration of temperature,
etc.) or patient-specific features (e.g. type of cancer, intensity of
anticancer regimen, trisomy 21) that would normally be used in
clinical decision rules. Therefore, associations between biomarker
and clinical outcomes found in this review do not account for the
complexity of multiple factors in an FN episode. The PICNICC (Pre-
dicting Infectious Complications of Neutropenic sepsis In Children
with Cancer) collaboration has collected data on 20 variables within
FN episodes including patient-specific clinical features and laboratory
variables.51 The influence of these multiple variables in predicting
FN outcomes can be better explored in such individual patient data
meta-analyses.
The outcomes explored in individual studies were relevant but
when grouping the outcomes of all the studies, there was consid-
erable overlap, for example, MDI and bacteraemia, CDI and sepsis,
bacteraemia and sepsis, or severe infection and bacteraemia. This
could explain the marked heterogeneity seen in the cross-hair plot
of biomarkers predicting different outcome groups (Supporting
Information S4). Better collaboration in future research is required
to provide consistency in outcome definitions.52 This review did not
find adequate data to perform meta-analyses on LOS in hospital or
community-based treatment (i.e. treatment duration) but the available
data for such outcomes are likely to be confounded by centre-specific
FN policy.
The biomarkers predictive ability decreased in sensitivity and
increased in specificity as the cutoff level increased. The potential use
of different biomarker assays between studies for a given threshold
may impact the reliability of the pSn and pSp results obtained, espe-
cially where fewer studies contributed to the pSp/pSn of a threshold.
The trade between an acceptable level of sensitivity and specificity is a
clinical decision and factors such as study/episode numbers and het-
erogeneity of data should be considered when deciding upon which
threshold to use in clinical practice.
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Comparative descriptions of the biomarkers found CRP to be the
poorest performing biomarker. The ILs possibly have a predictive role
within 24 h of admission but greater patient numbers and studies
are required to strengthen this finding. PCT is more discriminatory at
admission and performs better than CRP but its performance against
the ILs has only been explored in one study against IL-6.
The update found 12 out of 22 studies evaluated biomarkers at
serial time points. The previous systematic review23 identified only
six serial biomarker studies. Serial PCT studies in this review sup-
ported the findings of the previous review showing a better discrim-
inatory power over time with a rise interval of 24-48 h and then a
fall. The serial CRP results appear to show higher levels after 48-
72 h, which probably reflects its slower kinetic activity compared to
PCT53 implying CRP is not clinically useful in making decisions about
early de-escalation or cessation of treatment. This review found no
strongpredictive role of serial IL-6 and IL-8. Inconsistencies inmethod-
ology and reporting of outcomes would not allow meta-analyses of
these biomarkers to be performed. However, the descriptive findings
of these studies suggest encouraging results for the predictive use of
serial PCT and further studies using consistent methodological and
reporting approaches should focus in this area.
5 CONCLUSIONS
Biomarkers have been used to fortify existing clinical decision rules
in the management of FN. The choice of biomarker for predicting an
adverse outcome and the choice of optimal threshold remain incon-
clusive due to the variability within and between studies. However,
based on this review, PCT at a threshold of 0.5 ng/mL appears themost
suitable admission biomarker to predict adverse outcomes. There may
be additional benefit in using serial PCT measurements. This needs
to be validated through a larger multicentre study, using consistent
biomarker timings, assays and outcome definitions, beforewidespread
clinical recommendation and use.
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